CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how cancer patients who genetically have low signaling are seen to have better outcomes in than other genotypes.
View all episodes
By BiotechTV
4.3
66 ratings
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how cancer patients who genetically have low signaling are seen to have better outcomes in than other genotypes.
3,222 Listeners
1,910 Listeners
124 Listeners
324 Listeners
61 Listeners
9,957 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
512 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners